ArticleMethods in molecular biology (Clifton, N.J.)2025
Enhancing Cancer Vaccine Efficacy: siRNA-Based Modulation of Immune Suppressive Factors in Dendritic Cells.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cell (DC) cancer vaccines have become an established treatment modality for patients with a wide range of cancers. However, the therapeutic potential of this immunotherapy is often limited by negative feedback mechanisms that normally prevent sustained activation of the immune system, thereby reducing the risk of autoimmunity. To overcome these challenges, a new generation of DC vaccines have been developed using RNA interference (RNAi) technology to inhibit the expression of immunosuppressive factors, such as indoleamine 2,3-dioxygenase 1 (IDO1). The developed vaccines effectively stimulated T cells and demonstrated anti-tumor activity in cancer patients. This chapter describes the design and enzymatic synthesis of siRNA targeting IDO, along with its incorporation into DC vaccines under Good Manufacturing Practice.
Indexed as
Identifiers
40877509What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.